Payment overview · 2025
General Payments
$1,648.10
75 reported records · 18 companies
Healthcare provider profile · identity verified
Howard Michael Braver, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HOLLYWOOD, FL · NPI 1184672123
Verified facts
What the public records show
CMS Open Payments records show Howard Michael Braver, M.D. received $1,648.10 in general payments during 2025 across 75 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta, Xolair.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XOLAIR as an associated drug or biological on 5293 records involving 2861 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xolair by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $270.84 | 16.4% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $257.99 | 15.7% | 15 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $158.93 | 9.6% | 7 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $155.63 | 9.4% | 11 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $134.31 | 8.2% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $111.19 | 6.8% | 4 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $100.80 | 6.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $92.66 | 5.6% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $63.41 | 3.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.39 | 3.9% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.28 | 2.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.30 | 2.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.08 | 2.1% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $34.99 | 2.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $27.22 | 1.6% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $23.45 | 1.4% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $22.28 | 1.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.35 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,648.10 | 75 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $200.48 | 8 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $189.36 | 10 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $158.93 | 7 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $155.63 | 11 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $134.31 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $133.47 | 5 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $115.92 | 4 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $100.80 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $73.51 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $70.95 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $68.63 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $63.41 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.58 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.58 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.58 | 2 | 2025 |
Source payment records
|
|||||
| XOLAIR Normalized: xolair |
Drug | Novartis Pharmaceuticals Corporation | $38.28 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.30 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.30 | 2 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $35.08 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $34.99 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $27.22 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $23.45 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $4.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 75 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 254 | exact normalized | Medicare Part D |
| XOLAIR xolair |
2025 | Xolair | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
108 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
254 | 64 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | XOLAIR open payments reported associated product |
CMS Open Payments — General Payments 5293 supporting records · 2861 recipient NPIs · example record 1200005083 |
Xolair · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 456 | 162 |
| Alprazolam | Alprazolam | 408 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 334 | 113 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 299 | 107 |
| Losartan Potassium | Losartan Potassium | 285 | 92 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 254 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 234 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 221 | 67 |
| Zolpidem Tartrate | Zolpidem Tartrate | 209 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 204 | 69 |
| Omeprazole | Omeprazole | 180 | 63 |
| Simvastatin | Simvastatin | 172 | 49 |
| Tramadol Hcl | Tramadol Hcl | 172 | 44 |
| Gabapentin | Gabapentin | 148 | 39 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 144 | 110 |
| Lisinopril | Lisinopril | 141 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 45 |
| Metformin Hcl | Metformin Hcl | 136 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 33 |
| Methylprednisolone | Methylprednisolone | 124 | 84 |
| Lorazepam | Lorazepam | 122 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 44 |
| Symbicort | Budesonide/Formoterol Fumarate | 108 | 27 |
| Temazepam | Temazepam | 107 | 19 |
| Carvedilol | Carvedilol | 91 | 29 |
| Azithromycin | Azithromycin | 83 | 56 |
| Clonazepam | Clonazepam | 82 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 30 |
| Meclizine Hcl | Meclizine Hcl | 77 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 26 |
| Diazepam | Diazepam | 76 | 22 |
| Eliquis | Apixaban | 75 | 28 |
| Prednisone | Prednisone | 73 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 21 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 65 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 19 |
| Nifedipine Er | Nifedipine | 59 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 16 |
| Ibuprofen | Ibuprofen | 52 | 15 |
| Atenolol | Atenolol | 49 | 13 |
| Pregabalin | Pregabalin | 49 | 11 |
| Meloxicam | Meloxicam | 48 | 12 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 15 |
| Furosemide | Furosemide | 44 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 12 |
| Trazodone Hcl | Trazodone Hcl | 35 | 12 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 34 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 34 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | suppressed |
| Famotidine | Famotidine | 31 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | 11 |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 11 |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Erythromycin | Erythromycin Base | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Dupixent Pen | Dupilumab | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Xolair | Omalizumab | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Ofev | Nintedanib Esylate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,648.10 · 75 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, Arikayce, Brinsupri, COMIRNATY, Cologuard Collection Kit, DUPIXENT, Dexcom G6 Transmitter, ELIQUIS, FASENRA, JASCAYD, Korlym, LifeVest, NUCALA, NURTEC ODT, Ohtuvayre, Ozempic, PREVNAR 20, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, Rybelsus, TEZSPIRE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, WATCHMAN FLX, XOLAIR, YUPELRI | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error